New pill targets tough pancreatic cancer mutation

NCT ID NCT07644559

Recruiting now Disease control Sponsor: Verastem, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 17 times

Summary

This study tests a new oral drug, VS-7375, alone or with another drug (cetuximab), in 180 people with metastatic pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug shrinks tumors and is safe. Participants must have this mutation and be in relatively good health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VS-7375 (a pill that targets a specific cancer mutation) and cetuximab (an infusion drug)
What this could lead to: If successful, this could provide a new treatment option for people with a hard-to-treat form of pancreatic cancer that has a specific genetic mutation.
What could go wrong: This is a phase 2 trial, so it's still early. The drug may not work better than current treatments, and side effects could be significant. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

G12D MUTATED KRAS PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Contacts and locations

Locations

Cedars-Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
ICON Cancer Centre
RECRUITING

South Brisbane, QLD 4101, Australia
ICON Kurralta Park
RECRUITING

Kurralta Park, South Australia, 5037, Australia
Johns Hopkins University
RECRUITING

Baltimore, Maryland, 21287, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77054, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
NYU-Manhattan
RECRUITING

New York, New York, 10016, United States
START Dallas
RECRUITING

Fort Worth, Texas, 76104, United States
START Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
START New Jersey
RECRUITING

East Brunswick, New Jersey, 08816, United States
START- Los Angeles
RECRUITING

Los Angeles, California, 90025, United States
START- Mountain Region
RECRUITING

West Valley City, Utah, 84119, United States
START- San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
UVA Health
RECRUITING

Charlottesville, Virginia, 22903, United States
UW Health
RECRUITING

Madison, Wisconsin, 53792, United States
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States
University of North Carolina
RECRUITING

Chapel Hill, North Carolina, 27599, United States
Valkyrie Clinical Trials
RECRUITING

Los Angeles, California, 90067, United States
Virginia Cancer Specialists
RECRUITING

Fairfax, Virginia, 22031, United States
Virginia Mason
RECRUITING

Seattle, Washington, 98101, United States
Washington University
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.